Clinical Features and Patient Management of Lujo Hemorrhagic Fever

PLoS Neglected Tropical Diseases

Volumn 8, Issue 11, 2014, Pages

  Sewlall, Nivesh H ^a,b   Richards, Guy ^b   Duse, Adriano ^b   Swanepoel, Robert ^c   Paweska, Janusz ^d   Blumberg, Lucille ^d   Dinh, Thu Ha ^e   Bausch, Daniel ^f  

^a Internal Medicine Morningside MediClinic Johannesburg   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF PRETORIA   (South Africa)

^d National Institute of Communicable Diseases   (South Africa)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ANALGESIC AGENT; ANTIPYRETIC AGENT; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTATE DEHYDROGENASE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIBAVIRIN; ANTIVIRUS AGENT; BLOOD CLOTTING FACTOR 7A; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ADULT; ARENAVIRUS; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL FEATURE; DABOIA RUSSELLII; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; EPIDEMIOLOGY; ERYTHEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMORRHAGIC FEVER; HUMAN; LEUKOCYTOSIS; LEUKOPENIA; MALAISE; MALE; MIDDLE AGED; MYALGIA; PARTIAL THROMBOPLASTIN TIME; PATIENT CARE; RASH; SORE THROAT; SWELLING; THORAX PAIN; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE; VOMITING; ARENAVIRIDAE INFECTIONS; CASE REPORT; CROSS INFECTION; DRUG EFFECTS; EPIDEMIC; FATALITY; HEMORRHAGIC FEVERS, VIRAL; ISOLATION AND PURIFICATION; LASSA FEVER; LASSA VIRUS; PATHOLOGY; SOUTH AFRICA; VIROLOGY;

ACETYLCYSTEINE; ADULT; ANTIVIRAL AGENTS; ARENAVIRIDAE INFECTIONS; CROSS INFECTION; DISEASE OUTBREAKS; FACTOR VIIA; FATAL OUTCOME; FEMALE; HEMORRHAGIC FEVERS, VIRAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LASSA FEVER; LASSA VIRUS; LUJO VIRUS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RIBAVIRIN; SOUTH AFRICA;

EID: 84920424549     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003233     Document Type: Article

References (36)

1. CDCandWHO (1998) Infection control for viral haemorrhagic fevers in the African health care setting. Atlanta: Centers for Disease Control and Prevention. 1–198 p.
2. Gear JS, Cassel GA, Gear AJ, Trappler B, Clausen L, et al. (1975) Outbreak of Marburg virus disease in Johannesburg. Br Med J 4: 489–493.
3. Richards GA, Murphy S, Jobson R, Mer M, Zinman C, et al. (2000) Unexpected Ebola virus in a tertiary setting: clinical and epidemiologic aspects. Crit Care Med 28: 240–4.
4. Paweska JT, Sewlall NH, Ksiazek TG, Blumberg LH, Hale MJ, et al. (2009) Nosocomial outbreak of novel arenavirus infection, southern Africa. Emerg Infect Dis 15: 1598–1602.
5. Briese T, Paweska JT, McMullan LK, Hutchison SK, Street C, et al. (2009) Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog 5: e1000455.
6. Ishii A, Thomas Y, Moonga L, Nakamura I, Ohnuma A, et al. (2011) Novel arenavirus, Zambia. Emerg Infect Dis 17: 1921–1924.
7. Enria DA, Mills JN, Bausch D, Shieh W, Peters CJ (2011) Arenavirus Infections. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical Infectious Diseases: Principles, Pathogens, and Practice. 3 ed.Philadelphia: Churchill Livingstone. pp. 449–461.
8. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, et al. (1986) Lassa fever. Effective therapy with ribavirin. N Engl J Med 314: 20–26.
9. McCormick JB, King IJ, Webb PA, Johnson KM, O'Sullivan R, et al. (1987) A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis 155: 445–455.
10. Merx MW, Liehn EA, Janssens U, Lutticken R, Schrader J, et al. (2004) HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 109: 2560–2565.
11. Hackam DG, Mamdani M, Li P, Redelmeier DA, (2006) Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 367: 413–418.
12. Fisher-Hoch SP, Mitchell SW, Sasso DR, Lange JV, Ramsey R, et al. (1987) Physiological and immunologic disturbances associated with shock in a primate model of Lassa fever. J Infect Dis 155: 465–474.
13. Frame JD, Baldwin JM, JrGocke DJ, Troup JM, (1970) Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg 19: 670–676.
14. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES, (1987) A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis 155: 437–444.
15. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J, (2012) Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. PLoS One 7: e35797.
16. Troup JM, White HA, Fom AL, Carey DE, (1970) An outbreak of Lassa fever on the Jos plateau, Nigeria, in January-February 1970. A preliminary report. Am J Trop Med Hyg 19: 695–696.
17. Fisher-Hoch SP, Tomori O, Nasidi A, Perez-Oronoz GI, Fakile Y, et al. (1995) Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. Bmj 311: 857–859.
18. ProMed (2012) Lassa fever in France. Available: http://www.promedmail.org/?p=2400: 1000
19. McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, et al. (2014) Ebola Hemorrhagic Fever: Novel Biomarker Correlates of Clinical Outcome. J Infect Dis 210: 558–66.
20. Bausch DG (2011) 389: Viral Hemorrhagic Fevers. In: Goldman L, Schafer A, editors.Goldman's Cecil Medicine. 24th ed. pp. 2704.
21. Bausch DG, Sprecher AG, Jeffs B, Boumandouki P, (2008) Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions. Antiviral Res 78: 150–161.
22. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, et al. (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36: 296–327.
23. Kilgore PE, Ksiazek TG, Rollin PE, Mills JN, Villagra MR, et al. (1997) Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin Infect Dis 24: 718–722.
24. Barry M, Russi M, Armstrong L, Geller D, Tesh R, et al. (1995) Brief report: treatment of a laboratory-acquired Sabia virus infection. N Engl J Med 333: 294–296.
25. Enria DA, Briggiler AM, Sanchez Z, (2008) Treatment of Argentine hemorrhagic fever. Antiviral Res 78: 132–139.
26. Bausch DG, Hadi CM, Khan SH, Lertora JJ, (2010) Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis 51: 1435–1441.
27. Jones AL, (1998) Mechanism of action and value of N-acetylcysteine in the treatment of early and late acetaminophen poisoning: a critical review. J Toxicol Clin Toxicol 36: 277–285.
28. Paterson RL, Galley HF, Webster NR, (2003) The effect of N-acetylcysteine on nuclear factor-kappa B activation, interleukin-6, interleukin-8, and intercellular adhesion molecule-1 expression in patients with sepsis. Crit Care Med 31: 2574–2578.
29. Ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, et al. (1993) The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 92: 1207–1212.
30. Levi M, Peters M, Buller HR, (2005) Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 33: 883–890.
31. Stein DM, Dutton RP, Hess JR, Scalea TM, (2008) Low-dose recombinant factor VIIa for trauma patients with coagulopathy. Injury 39: 1054–1061.
32. Giusti-Paiva A, Martinez MR, Felix JV, da Rocha MJ, Carnio EC, et al. (2004) Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. Shock 21: 271–275.
33. Cornejo R, Downey P, Castro R, Romero C, Regueira T, et al. (2006) High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med 32: 713–722.
34. Bird BH, Dodd KA, Erickson BR, Albarino CG, Chakrabarti AK, et al. (2012) Severe hemorrhagic fever in strain 13/N guinea pigs infected with Lujo virus. PLoS Negl Trop Dis 6: e1801.
35. Khan SH, Goba A, Chu M, Roth C, Healing T, et al. (2008) New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res 78: 103–115.
36. Bausch DG, Demby AH, Coulibaly M, Kanu J, Goba A, et al. (2001) Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations. Vector Borne Zoonotic Diseases 1: 269–281.